Porsolt

Executive Summary

Porsolt is a globally recognized Contract Research Organization (CRO) specializing in preclinical drug development for neuroscience and drug delivery. Founded in 1985 and headquartered in Le Genest-Saint-Isle, France, the company provides comprehensive services to clients across all stages of preclinical research. Porsolt is GLP compliant and AAALAC accredited, ensuring high-quality, regulatory-standard studies. Its expertise spans behavioral pharmacology, safety pharmacology, pharmacokinetics, and toxicology, supporting biotech and pharmaceutical companies in advancing drug candidates toward clinical trials. Despite being a private company with no disclosed funding or pipelines, Porsolt's established reputation and accreditations position it as a reliable partner in the competitive preclinical CRO market. The company's long operating history and focus on neuroscience align with growing demand for CNS therapies. However, as a service provider, its growth is tied to client acquisition and project volume, which may be influenced by broader R&D spending trends.

Upcoming Catalysts (preview)

• 2026Expansion of preclinical service offerings or facility upgrades65% success
• Q3 2026Major contract win with a large pharma or biotech collaborator40% success
• H2 2026Regulatory accreditation renewal or new certification (e.g., OECD)90% success